Adenoma Detection Rate, or ADR, is a quality measure for endoscopy facilities and professionals that is defined as “the rate at which a physician finds one or more precancerous polyps during a normal screening colonoscopy procedure for patients over 50 years old.” Professional societies, including the American College of Gastroenterology (ACG), have determined the benchmark rate should be at least 25% in men and 15% in women.
A look at the future The future of AI in gastroenterology is very exciting. Advances are coming almost faster than the industry is able to keep pace with. As we move forward here are some of the areas to follow: Enhanced voice to text Voice to Text has become fairly commonplace in GI documentation solutions, replacing the popular process of manually transcribing and coding procedures notes that were dictated by a physician into a recording device. However, today, the text collected is very likely to be “free text” and not tied to discrete data and automated coding. That means any procedure notes captured using Voice to Text still requires significant manual review and coding and will be nearly impossible to data mine.
For any site that performs gastrointestinal (GI) procedures, determining endoscopy ADRs Providers should start asking and understanding their importance is crucial. patients if they would like AI Physicians with the best ADRs are most successful to be a part of their care plan. in detecting precancerous adenomas in the colon and helping patients avoid colorectal cancer. In fact, according to the New England Journal of Medicine, for every 1% increase in a physician’s ADR, a person’s risk of developing colon cancer AI can enhance Voice to Text enabling the over the next year decreases by 3%. Risk of death decreases by 5%. captured text to be automatically converted into structured data, making it AI for clinical trials available immediately for data mining and analytics, quality reporting, and AI has a broad application in clinical trials, including that of assisting clinical trial recruitment–drastically reducing manual entry, calculations, with clinical trial recruitment through the automated surfacing and and human error. qualification of patients into the trial as well as automated end-point Intefrated AI-powered scopes and documentation software scoring or determination of severity of diseases. We are working on Today, AI-augmented polyp detection is normally done at the scope a few such projects including being able to replicate currently used endoscopic severity grading but with a lower variance and bias, and higher The Future of Gastroenterology to page 314 reproducibility than clinicians are able to achieve on their own.
Partnering with eye care professionals to achieve their full business and strategic potential
Associated Eye Care Partners (AECP) is a Minnesota-based eye care practice management service organization. We provide capital and a full range of practice management services. We do not buy practices. When you partner with us you retain your independence. For more information contact:
Daniel K. Zismer, Ph.D., Co-Chair and CEO; dzismer@aecpmso.com Gary S. Schwartz, MD, MHA, Co-Chair and Executive Medical Director; gschwartz@aecpmso.com
www.aecpmso.com
MINNESOTA PHYSICIAN APRIL 2021
15
